Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acne Vulgaris
CollaGenex Pharmaceuticals Initiates 40 mg Cohort in the Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
April 10th, 2007
CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) announced that it has initiated enrollment in a 40 mg cohort in its Phase II double-blinded, placebo-controlled, dose-finding clinical trial to determine the appropriate dose for Phase III testing of incyclinide in the treatment of acne. The 40 mg cohort will enroll 100 patients with moderate-to-severe acne at 13 investigational centers across the United States. The placebo-controlled study will evaluate a daily 40 mg dose of incyclinide over a 12 week period. Klaus Theobald, M.D., Ph.D., chief medical officer of CollaGenex, said, "We are extremely encouraged that the analysis of the 5, 10, and 20 mg cohorts demonstrated a...
Source: Drug Law Weekly (2007-04-10)
|
